Bringing science to wellbeing
Weston, et al. Effects of probiotics on atopic dermatitis: a randomised controlled trial. Archives of Diseases in Childhood. 2005;90:892-897
The study investigated the effects of PCC® on moderate and severe atopic dermatitis (eczema) in infants aged 6-18 months. The study was conducted in Western Australia at the Institute for Child Health as a randomised, double blind, placebo controlled clinical trial. 53 children completed the study. The children were divided into two groups and given either PCC® (1 billion CFU) or a placebo for eight weeks.
The severity and extent of eczema symptoms was assessed using the SCORAD index at baseline and at eight and 16 weeks. A significant reduction in eczema symptoms was seen in the PCC® group but not in the placebo group. Furthermore, this improvement continued for at least eight weeks after dosing was completed.
The authors concluded that “supplementation with PCC® is beneficial in improving the extent and severity of atopic dermatitis in young children with moderate or severe disease”. As a secondary benefit, the study also showed that significantly fewer infants who were given PCC® had lower respiratory tract infections compared to the placebo group.
Read a summary of the study and its findings
Suite 506, Level 550 Clarence St
Sydney, NSW 2000, Australia
P: +61 2 9078 8180
ABN: 97 084 464 193
Which of the following group do you best fit?